Portable MRI specialist Hyperfine announces plans to expand overseas

Portable MRI specialist Hyperfine Inc. is expanding overseas into two new countries, the company announced Tuesday.

The Guilford, Connecticut, firm plans to set up shop in the U.K. and Pakistan. It’s the start of a larger commercial expansion goal to enter four additional countries within the next six months.

Hyperfine’s U.K. endeavor will be led by Yossi Cohen, MD, who has been hired as U.K senior medical director. Cohen will oversee clinical and commercial operations along with regulatory efforts.

In Pakistan, Omer Manya will be responsible for building up the Swoop modality’s presence. Medequips, a local imaging specialist, will take on the marketing, distribution and sales of the system throughout the country.

“The promise of Hyperfine is to dramatically increase the presence of MRI in clinical environments around the world,” President and CEO Dave Scott said in a statement. “Expansion to the U.K. and Pakistan is a milestone moment and tremendous opportunity as we step forward to meet the global demand for better imaging access and ultimately drive a more comprehensive and efficient care continuum.”

Hyperfine first made waves in February 2020 after the U.S. Food and Drug Administration cleared its Swoop technology for pediatric brain imaging. And earlier this year, the firm secured a $90 million infusion of capital to “aggressively” advance its commercial expansion efforts.

The imaging disrupter recently went public on the Nasdaq with a $580 million valuation. It also combined with brain measurement specialist Liminal Sciences to form a special-purpose acquisition company based in the Cayman Islands.

Around the web

More healthcare professionals are desperately needed over the next decade, but some roles are more in demand than others. 

 

Retail giant Walmart has teamed up with Transcarent, a health and care platform, to provide a go-to-market solution for self-insured employers and their families.

 

Women’s health specialists have demonstrated the customization of a commercial AI-based chatbot platform for patients with hereditary breast and ovarian cancer. The pilot project took many hands and much manual labor to complete, but the team suggests the effort has been worth the payoffs.

Trimed Popup
Trimed Popup